ArticleACS infectious diseases2021
Prioritization of Molecular Targets for Antimalarial Drug Discovery.
Abstract read
In one paragraph
Article in ACS infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- Identification, Structure-Activity Relationship (SAR), and Biological Evaluation of New Chemical Series as Malaria ParasiteACS omega · 2026Article
- Revisiting Glutathione Transferases ofPharmaceuticals (Basel, Switzerland) · 2026Review
- Minimum Inoculum of Resistance Assay for Evaluating Antitoxoplasmosis Compounds That Target Phenylalanine tRNA Synthetase.ACS infectious diseases · 2026Article
- Identification of an Orally Efficacious Imidazo[4,5-Journal of medicinal chemistry · 2026Article
- Targeting protein-protein interactions in Plasmodium: from asexual replication to sexual development.Parasites & vectors · 2026Review
- Novel Antiplasmodial Natural Products Identified Through a Modified Bioluminescence-Based Rate-of-Kill Assay.Biomedicines · 2026Article
- Minimum inoculum of resistance assay for evaluating for anti-toxoplasmosis compounds that target phenyl alanine tRNA synthetase.bioRxiv : the preprint server for biology · 2026Article
- Article
- Investigation of a cryptic ligand binding site on Plasmodium falciparum Hsp90.Bioorganic & medicinal chemistry · 2025Article
- Article
- Article
- Plasmodiumfalciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity.Cell chemical biology · 2025Article
- Structure-activity analysis of imino-pyrimidinone-fused pyrrolidines aids the development of dual plasmepsin V and plasmepsin X inhibitors.The FEBS journal · 2025Article
- The essential genome ofScience (New York, N.Y.) · 2025Article
- YAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates.Scientific reports · 2025Article
- Antimalarial Drug Discovery from Natural and Synthetic Sources.Current medicinal chemistry · 2025Review
- Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials.Nature communications · 2024Article
- β-Carboline-3-carboxamide Antimalarials: Structure-Activity Relationship, ADME-Tox Studies, and Resistance Profiling.ACS infectious diseases · 2024Article
- Onametostat, a PfPRMT5 inhibitor, exhibits antimalarial activity toAntimicrobial agents and chemotherapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Barbara ForteWellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, DD1 5EH, United Kingdom.
Sabine OttilieDepartment of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0001-9797-2612
Andrew PlaterWellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, DD1 5EH, United Kingdom.
Brice CampoMedicines for Malaria Venture, 1215 Geneva, Switzerland.
Koen J DecheringTropIQ Health Sciences, 6534 AT, Nijmegen, The Netherlands.
Francisco Javier GamoGlobal Health, GSK, 28760-Tres Cantos, Madrid, Spain.ORCID 0000-0002-1854-2882
Daniel E GoldbergDivision of Infectious Diseases, Department of Medicine and Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States.ORCID 0000-0003-3529-8399
Eva S IstvanDivision of Infectious Diseases, Department of Medicine and Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Marcus LeeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, United Kingdom.
Amanda K LukensInfectious Disease and Microbiome Program, Broad Institute, Cambridge, Massachusetts 02142, United States.ORCID 0000-0002-9560-7643
Case W McNamaraCalibr, a Division of The Scripps Research Institute, 11119 North Torrey Pines Road, La Jolla, California 92037, United States.ORCID 0000-0002-5754-3407
Jacquin C NilesDepartment of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge Massachusetts 02139-4307, United States.ORCID 0000-0002-6250-8796
John OkomboDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States.
Charisse Flerida A PasajeDepartment of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge Massachusetts 02139-4307, United States.
Miles G SiegelLgenia, Inc., Fortville, Indiana 46040, United States.
Dyann WirthInfectious Disease and Microbiome Program, Broad Institute, Cambridge, Massachusetts 02142, United States.
Susan WyllieWellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, DD1 5EH, United Kingdom.ORCID 0000-0001-8810-5605
David A FidockDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States.
Beatriz BaragañaWellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, DD1 5EH, United Kingdom.ORCID 0000-0002-0959-1113
Elizabeth A WinzelerDepartment of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-4049-2113
Ian H GilbertWellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, DD1 5EH, United Kingdom.ORCID 0000-0002-5238-1314
Funding
Discovery of long-acting, chemoprotective antimalarial compoundsR01AI152533 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2020 to 2024
$3.5MNIAID NIH HHS R01 AI152533Wellcome TrustWellcome Trust 203134/Z/16/Z
Abstract
There is a shift in antimalarial drug discovery from phenotypic screening toward target-based approaches, as more potential drug targets are being validated in
Indexed as
AntimalarialsMalariaPlasmodiumDrug DiscoveryHumansAntimalarialsdrug discoverymalariamolecular targetsPlasmodium
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.